Atlas Genetics Inc., headquartered in the United States, is a pioneering company in the field of molecular diagnostics. Founded in 2005, the company has made significant strides in developing innovative testing solutions that enhance patient care. With a focus on sexually transmitted infections (STIs) and other infectious diseases, Atlas Genetics offers unique point-of-care testing systems that deliver rapid and accurate results. The company’s flagship product, the io® system, stands out for its ability to provide lab-quality results in a compact format, making it ideal for diverse healthcare settings. Atlas Genetics has established a strong market position, recognised for its commitment to improving diagnostic accessibility and efficiency. As the demand for rapid testing continues to grow, Atlas Genetics remains at the forefront of the molecular diagnostics industry, driving advancements that benefit both healthcare providers and patients alike.
How does Atlas Genetics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Atlas Genetics Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Atlas Genetics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary, Atlas Genetics Inc. may inherit climate-related data and initiatives from its parent organisation; however, no specific details or metrics have been provided regarding such cascaded information. This absence of data limits the ability to assess the company's climate commitments or performance in relation to industry standards. In the broader context, companies in the biotechnology sector are increasingly recognising the importance of sustainability and are often encouraged to adopt science-based targets to mitigate climate impact. However, without specific emissions data or reduction initiatives, Atlas Genetics Inc. remains unquantified in its climate commitments.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Atlas Genetics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.